IN8BIO, INC.
Close on Oct 19, 2026
- Market cap
- $21.22M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | – | $-0.25 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | $-0.26 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | During market hours | – | $-0.45 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | – | $-0.85 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | $-1.24 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | During market hours | – | $-0.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | – | $-0.15 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | $-0.19 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | $-0.20 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | During market hours | – | $0.22 | – |
Press releases
Announcements In8bio filed with the SEC
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Executive or director change · Shareholder vote results · EX-99.1 to Form 8-K
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
Other events · EX-99.1 to Form 8-K
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed
Other events · EX-99.1 to Form 8-K
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
Other events · EX-99.1 to Form 8-K
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
( g d ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
Other events · EX-99.1 to Form 8-K
IN8bio Reports Updated Positive Results from Phase 1 Trial of
Other events · EX-99.1 to Form 8-K
IN8bio Reports Continued Progression-Free Survival in
Other events · EX-99.1 to Form 8-K
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of
Other events · EX-99.1 to Form 8-K
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta
Other events · EX-99.1 to Form 8-K
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Presents Positive Data Demonstrating Durable 1-year
Shareholder vote results · Other events · EX-99.1 to Form 8-K
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of
Other events · EX-99.1 to Form 8-K
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
IN8bios INB-200 Demonstrates Extended Progression-Free
Other events · EX-99.1 to Form 8-K
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a
Other events · EX-99.1 to Form 8-K
IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
IN8bio Announces Positive INB-200 Phase 1 Data Update in
Other events · EX-99.1 to Form 8-K
IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Other events · EX-99.1 to Form 8-K
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
IN8bio Presents Positive, New INB-100 Data Showing Long-term
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at
Other events · EX-99.1 to Form 8-K
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
IN8bio Presents Preclinical Data Showing Non-Signaling CAR
Other events · EX-99.1 to Form 8-K
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
Other events · EX-99.1 to Form 8-K
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete
Other events · EX-99.1 to Form 8-K
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400
Other events · EX-99.1 to Form 8-K
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K/A
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
Regulation FD disclosure · EX-99.1 to Form 8-K